Difference between revisions of "Olaratumab (Lartruvo)"
m (→References) |
m |
||
Line 1: | Line 1: | ||
+ | '''Note: as of April 2019, the manufacturer has decided to discontinue the product after the confirmatory RCT was negative.''' | ||
+ | |||
=General information= | =General information= | ||
Class/mechanism: Human IgG1 antibody that blocks the activity of platelet-derived growth factor receptor alpha (PDGFR-α). Olaratumab prevents binding of PDGF-AA and -BB ligands to PDGFR-α and blocks PDGF-AA, -BB, and -CC-induced receptor activation and downstream PDGFR-α pathway signaling, including the MAPK and PI3K pathways. PDGFR-α is a receptor tyrosine kinase expressed on mesenchymal origin cells, and signaling through PDGFR-α is involved in cell growth, chemotaxis, and mesenchymal stem cell differentiation.<ref name="insert">[http://pi.lilly.com/us/lartruvo-uspi.pdf Olaratumab (Lartruvo) package insert]</ref><ref>[[Media:Olaratumab.pdf | Olaratumab (Lartruvo) package insert (locally hosted backup)]]</ref><ref>[http://lartruvo.com/ Lartruvo manufacturer's website]</ref><ref>[https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=626630 NCI Drug Dictionary entry for olaratumab]</ref> | Class/mechanism: Human IgG1 antibody that blocks the activity of platelet-derived growth factor receptor alpha (PDGFR-α). Olaratumab prevents binding of PDGF-AA and -BB ligands to PDGFR-α and blocks PDGF-AA, -BB, and -CC-induced receptor activation and downstream PDGFR-α pathway signaling, including the MAPK and PI3K pathways. PDGFR-α is a receptor tyrosine kinase expressed on mesenchymal origin cells, and signaling through PDGFR-α is involved in cell growth, chemotaxis, and mesenchymal stem cell differentiation.<ref name="insert">[http://pi.lilly.com/us/lartruvo-uspi.pdf Olaratumab (Lartruvo) package insert]</ref><ref>[[Media:Olaratumab.pdf | Olaratumab (Lartruvo) package insert (locally hosted backup)]]</ref><ref>[http://lartruvo.com/ Lartruvo manufacturer's website]</ref><ref>[https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=626630 NCI Drug Dictionary entry for olaratumab]</ref> | ||
Line 6: | Line 8: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
− | ==Diseases for which it | + | ==Diseases for which it was used== |
*[[Soft tissue sarcoma|Soft tissue sarcoma]] | *[[Soft tissue sarcoma|Soft tissue sarcoma]] | ||
Line 13: | Line 15: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
− | *10/19/2016: | + | *10/19/2016: Accelerated approval for the treatment of patients with [[Soft tissue sarcoma|soft tissue sarcoma (STS)]] not amenable to curative treatment with radiotherapy or surgery and with a histologic subtype for which an anthracycline-containing regimen is appropriate. |
==Also known as== | ==Also known as== | ||
Line 30: | Line 32: | ||
[[Category:Soft tissue sarcoma medications]] | [[Category:Soft tissue sarcoma medications]] | ||
[[Category:FDA approved in 2016]] | [[Category:FDA approved in 2016]] | ||
+ | [[Category:Discontinued]] |
Revision as of 16:09, 7 June 2019
Note: as of April 2019, the manufacturer has decided to discontinue the product after the confirmatory RCT was negative.
General information
Class/mechanism: Human IgG1 antibody that blocks the activity of platelet-derived growth factor receptor alpha (PDGFR-α). Olaratumab prevents binding of PDGF-AA and -BB ligands to PDGFR-α and blocks PDGF-AA, -BB, and -CC-induced receptor activation and downstream PDGFR-α pathway signaling, including the MAPK and PI3K pathways. PDGFR-α is a receptor tyrosine kinase expressed on mesenchymal origin cells, and signaling through PDGFR-α is involved in cell growth, chemotaxis, and mesenchymal stem cell differentiation.[1][2][3][4]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it was used
Patient drug information
- Brief patient counseling information can be found in the Olaratumab (Lartruvo) package insert [1]
History of changes in FDA indication
- 10/19/2016: Accelerated approval for the treatment of patients with soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery and with a histologic subtype for which an anthracycline-containing regimen is appropriate.
Also known as
- Code names: LY3012207, IMC-3G3
- Brand name: Lartruvo